Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.42 USD
+0.06 (1.79%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $3.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Arbutus Biopharma Corporation [ABUS]
Reports for Purchase
Showing records 81 - 100 ( 191 total )
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Thinning Pipeline Terminates Another Hepatitis B Asset. Moving To SELL While Pipeline Priorities Continue To Evolve
Provider: Echelon Welath Partners
Analyst: LOE D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
AB-506 Discontinued due to Liver Tox.; Reducing Price Target to $1 (from $3)
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Thinning Pipeline Terminates Another Hepatitis B Asset. Moving To SELL While Pipeline Priorities Continue To Evolve
Provider: Echelon Welath Partners
Analyst: LOE D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
2019 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials; Triple Combo Study Remains in Sight
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Flares Feature in Ph 1 Capsid Inhibitor Study Preliminary Data
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Onpattro Royalty Sale Extends Cash Runway While Maintaining Future Economics
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R